albuterol and Dermatitis, Eczematous

albuterol has been researched along with Dermatitis, Eczematous in 3 studies

Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.
albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).

Research

Studies (3)

Authors

Clinical Trials (3)

Trial Overview

Trial Outcomes

Change From Baseline in Asthma Quality of Life

Asthma quality of life is measured as the average of 23 questions, each of which is scored from 1 (worse) to 7 (best) (NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period

Change From Baseline in the Asthma Control Test (ACT)

The ACT consists of five items, each scored as 1 (worst) to 5 (best). The five items are averaged. (NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period

Change From Baseline in the Evening Peak Expiratory Flow Rate (PEFR) % Predicted

(NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period

Change From Baseline in the Impulse Oscillometry Resistance at 5 Hertz

Change from baseline in the impulse oscillometry resistance at 5 Hertz, measured in kiloPascals per liters per second (NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period

Change From Baseline in the Logarithm Base 2 of the Methacholine PC20

The methacholine PC20 is the concentration of methacholine that causes a 20% decrease in the pre-bronchodilator FEV1. The logarithm base 2 transformation converts the PC20 into doubling dilutions. (NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period

Change From Baseline in the Morning Peak Expiratory Flow Rate (PEFR) % Predicted

(NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period

Change From Baseline in the Natural Logarithm of Exhaled Nitric Oxide (eNO)

(NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period

Change From Baseline in the Peak Expiratory Flow Rate (PEFR) Variability

PEFR variability is calculated as 100% times the difference between the evening and morning PEFR values, divided by the average of the evening and morning PEFR values, i.e., PEFR variability = 100% x (morning PEFR - evening PEFR)/((morning PEFR + evening PEFR)/2) (NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period

Change From Baseline in the Post-bronchodilator FEV1 Percent Predicted

(NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period

Change From Baseline in the Pre-bronchodilator FEV1/FVC Ratio

(NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period

Change From Baseline in the Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) % Predicted

(NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period

Change From Baseline in the Pre-bronchodilator Forced Vital Capacity (FVC) % Predicted

(NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period

Number of Participants With Asthma Exacerbations

An asthma exacerbation was defined as the administration of a course of oral/systemic prednisone for the treatment of asthma. (NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period

The Number of Participants With a Differential Response to the Three Step-up Therapies Based on Fixed Threshold Criteria for the Following Three Asthma Control Measures: Use of Oral Prednisone for Acute Asthma Exacerbations, Asthma Control Days and FEV1.

One treatment period was ranked as better than another if the total amount of prednisone received during the period was at least 180 mg less, if the number of annualized asthma-control days during the final 12 weeks of the period was increased by at least 31 days, or if the FEV1 at the end of the period was at least 5% higher. If the prednisone threshold was met, then we ignored the number of asthmacontrol days and the FEV1. If the threshold for asthma-control days was met, then we ignored the FEV1. Otherwise, the order of response was determined by the FEV1. (NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period

Trials

2 trials available for albuterol and Dermatitis, Eczematous

Other Studies

1 other study available for albuterol and Dermatitis, Eczematous